Regeneron Pharmaceuticals Inc. (REGN): Price and Financial Metrics


Regeneron Pharmaceuticals Inc. (REGN): $686.02

4.11 (+0.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add REGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

REGN POWR Grades


  • Quality is the dimension where REGN ranks best; there it ranks ahead of 90% of US stocks.
  • The strongest trend for REGN is in Sentiment, which has been heading down over the past 179 days.
  • REGN's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

REGN Stock Summary

  • Regeneron Pharmaceuticals Inc's market capitalization of $75,807,090,727 is ahead of 96.48% of US-listed equities.
  • Over the past twelve months, REGN has reported earnings growth of 142.63%, putting it ahead of 85.9% of US stocks in our set.
  • As for revenue growth, note that REGN's revenue has grown 89.14% over the past 12 months; that beats the revenue growth of 90.83% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Regeneron Pharmaceuticals Inc are SNPS, LRCX, CDNS, MU, and NXPI.
  • REGN's SEC filings can be seen here. And to visit Regeneron Pharmaceuticals Inc's official web site, go to www.regeneron.com.

REGN Valuation Summary

  • In comparison to the median Healthcare stock, REGN's price/sales ratio is 48.9% lower, now standing at 5.8.
  • REGN's price/sales ratio has moved down 24.1 over the prior 243 months.
  • Over the past 243 months, REGN's EV/EBIT ratio has gone up 38.2.

Below are key valuation metrics over time for REGN.

Stock Date P/S P/B P/E EV/EBIT
REGN 2021-08-31 5.8 4.8 11.6 10.0
REGN 2021-08-30 5.8 4.8 11.7 10.0
REGN 2021-08-27 5.7 4.7 11.4 9.8
REGN 2021-08-26 5.7 4.7 11.5 9.8
REGN 2021-08-25 5.8 4.7 11.5 9.9
REGN 2021-08-24 5.8 4.7 11.5 9.9

REGN Growth Metrics

    Its 4 year price growth rate is now at 52.06%.
  • The 3 year cash and equivalents growth rate now stands at 182.76%.
  • The 5 year net income to common stockholders growth rate now stands at 214.05%.
REGN's revenue has moved up $9,160,585,000 over the prior 34 months.

The table below shows REGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 16,071.7 7,081.3 8,075.3
2021-09-30 13,542.9 5,939.8 6,995.5
2021-06-30 12,384.1 2,271.9 6,205.4
2021-03-31 9,197.6 2,588.6 4,003.8
2020-12-31 8,497.1 2,618.1 3,513.2
2020-09-30 8,243.7 2,174.5 3,156

REGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • REGN has a Quality Grade of B, ranking ahead of 86.94% of graded US stocks.
  • REGN's asset turnover comes in at 0.683 -- ranking 43rd of 681 Pharmaceutical Products stocks.
  • JAZZ, AGLE, and VERU are the stocks whose asset turnover ratios are most correlated with REGN.

The table below shows REGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.683 0.868 0.456
2021-03-31 0.562 0.868 0.315
2020-12-31 0.536 0.868 0.292
2020-09-30 0.540 0.880 0.283
2020-06-30 0.543 0.882 0.282
2020-03-31 0.553 0.897 0.221

REGN Price Target

For more insight on analysts targets of REGN, see our REGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $683.25 Average Broker Recommendation 1.52 (Moderate Buy)

REGN Stock Price Chart Interactive Chart >

Price chart for REGN

REGN Price/Volume Stats

Current price $686.02 52-week high $747.42
Prev. close $681.91 52-week low $492.13
Day low $667.75 Volume 465,100
Day high $686.33 Avg. volume 703,528
50-day MA $680.14 Dividend yield N/A
200-day MA $638.05 Market Cap 74.46B

Regeneron Pharmaceuticals Inc. (REGN) Company Bio


Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester CountyNew York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors. (Wikipedia:Source)


REGN Latest News Stream


Event/Time News Detail
Loading, please wait...

REGN Latest Social Stream


Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about Regeneron Pharmaceuticals Inc that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Kodiak Sciences: KSI-301 Disappoints

Kodiak Sciences' (KOD) KS-301 is an anti-VEGF biologic for the treatment of retinal diseases. The crucial product attribute being assessed in the phase 3 trial was the ability to meaningfully extend the treatment interval while showing non-inferior visual acuity gains compared to aflibercept administered every eight weeks. The study failed...

Sage Advisors on Seeking Alpha | February 25, 2022

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Yahoo | February 24, 2022

KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?

Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session.

Chris MacDonald on InvestorPlace | February 23, 2022

Thinking about trading options or stock in Block, Mercadolibre, Futu, GameStop, or Regeneron Pharmaceuticals?

NEW YORK , Feb. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SQ, MELI, FUTU, GME, and REGN. Full story available on Benzinga.com

Benzinga | February 23, 2022

Why Kodiak Sciences Shares Are Plunging Today

Kodiak Sciences Inc (NASDAQ: KOD ) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial did not meet the primary efficacy endpoint of showing non-inferior visual acuity gains for subjects dosed on extended regimens compared to Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Eylea (aflibercept) given every eight Full story available on Benzinga.com

Benzinga | February 23, 2022

Read More 'REGN' Stories Here

REGN Price Returns

1-mo -0.62%
3-mo 12.50%
6-mo 6.63%
1-year 37.75%
3-year 119.48%
5-year 50.72%
YTD 8.63%
2021 30.72%
2020 28.66%
2019 0.53%
2018 -0.65%
2017 2.42%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5849 seconds.